Navigation Links
Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
Date:1/11/2008

ucts and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Transition Report on Form 10-K/T for the six months ended December 31, 2006.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.


'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
6. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. Pressure BioSciences, Inc. Issued First Patent in Canada
9. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
10. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
11. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- , Not for release, publication or distribution ... jurisdiction where to do so would constitute a violation of ... ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG ... has held a meeting with representatives of AbbVie. ... agreement or approval of AbbVie. A further update ...
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... 7 When leading contract research,organization Pharm-Olam International (POI, ... voice-over Internet protocol (VoIP),system that would better serve the ... catastrophic., POI initially selected a local vendor to ... immediately clear the solution was a bigger problem,than the ...
... LifeQuest World Corporation,(OTC Bulletin Board: LQWC) is pleased ... ImmunXT, their Immune System enhancement supplement, has,been released ... of March 2008.,ImmunXT has been proclaimed as "the ... (US Patent #7,205,284 B2),is a bio-active Micro-algae Complex ...
... Eastern Time -, SOUTH SAN FRANCISCO, Calif., May ... biopharmaceutical company focused,on oncology, today reported on its corporate ... 31, 2008., "During the first quarter, we made ... data to demonstrate the potential of,picoplatin as a new ...
Cached Biology Technology:Pharm-Olam Finds VoIP Solution in Taridium LLC 2LifeQuest World Launches Immune System Boosting Supplement to the North American Market 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 9
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)... Florida , July 1, 2014 ... pave way for convenience and improved security: NXT-ID, Inc. (OTCBB: ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a ... pleased to announce that the second series of 30 second ...
(Date:7/10/2014)... , July 3, 2014 Research ... addition of the "Global Gesture Recognition & ... - Forecasts to 2020" report to their ... Global Gesture Recognition & Touch-Less Sensing Market ... around for a while, but the companies were ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... and treatment of breast cancer, the disease remains a ... technology under investigation at the Biodesign Institute at Arizona ... cell nuclear structure, the molecular biosignature of cancer, thus ... detection of the disease. The team, led by ...
... half years since Adam Bogdanove, professor at Iowa State University ... Matthew Moscou, a former graduate student in that department, discovered ... and bind specific sequences in plant genomes, researchers worldwide have ... was first shown that the proteins can be fused to ...
... Scientists have uncovered a lot about the Earth,s greatest ... rapid climate change wiped out nearly all marine species and ... a new culprit likely involved in the annihilation: an influx ... looked to see if mercury was a potential culprit. This ...
Cached Biology News:Cell-CT: A new dimension in breast cancer research 2Cell-CT: A new dimension in breast cancer research 3Cell-CT: A new dimension in breast cancer research 4ISU scientist helps find structure of gene-editing protein named Method of the Year 2Earth's massive extinction: The story gets worse 2
... Automatic grid, subgrid and spot finding overcome tedious spot, ... template assignment , ... options to optimize, ... Characterize more precisely through grouping by cells, grids, ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... liter of urine will give a positive reaction ... ,Certification: The Donors are of US origin ... NEGATIVE for HbsAg, HCV, HIV-1 & 2, Syphilis ... THIS MATERIAL IS SOLD FOR IN-VITRO DIAGNOSTIC USE ...
Biology Products: